Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
COVID-19
Heterologous
adults
homologous
inactivated
vaccine
viral vectored
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
31 12 2022
31 12 2022
Historique:
pubmed:
26
2
2022
medline:
12
4
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity and immunogenicity of the heterologous adenoviral vector (ChAdOx1-S, AstraZeneca; hereafter referred to as AZ) and the inactivated vaccine regimen (CoronaVac; hereafter referred to as CV) in healthy Thai adults immunized between June and September 2021. Our study showed that adverse events following homologous CV-CV and AZ-AZ, and heterologous CV-AZ and AZ-CV combinations, were mild and well tolerated overall. Receptor-binding domain (RBD)-specific antibody responses and neutralizing activities against wild-type and variants of concern after two-dose vaccination were higher in the heterologous CV-AZ and homologous AZ-AZ groups compared to the CV-CV and AZ-CV groups. Conversely, the spike-specific IgA response was detected only in the CV-AZ group after two doses of vaccination. The total interferon gamma response was detected in both the CV-AZ and AZ-CV groups after the two-dose vaccination. Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.
Identifiants
pubmed: 35209809
doi: 10.1080/21645515.2022.2029111
pmc: PMC8993087
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2029111Références
Vaccine. 2016 Apr 12;34(17):2008-14
pubmed: 26954467
J Med Virol. 2022 Apr;94(4):1442-1449
pubmed: 34783049
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Emerg Infect Dis. 2021 Dec;27(12):3178-3180
pubmed: 34559045
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
N Engl J Med. 2021 Sep 9;385(11):1049-1051
pubmed: 34260850
Vaccine. 2022 Jan 24;40(3):524-530
pubmed: 34893344
Infect Dis Ther. 2021 Dec;10(4):2765-2776
pubmed: 34435336
Nat Med. 2021 Sep;27(9):1525-1529
pubmed: 34262158
Clin Infect Dis. 2022 Apr 9;74(7):1315-1316
pubmed: 34383902
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Vaccine. 2021 Oct 22;39(44):6520-6528
pubmed: 34620531
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Mol Med Rep. 2021 Aug;24(2):
pubmed: 34132379
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
Clin Infect Dis. 2021 Sep 19;:
pubmed: 34537835
Cell Mol Immunol. 2021 Oct;18(10):2455-2456
pubmed: 34426672
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
J Med Virol. 2021 Apr;93(4):2177-2195
pubmed: 33095454
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554
Lancet. 2021 May 29;397(10289):2043-2046
pubmed: 33991480
Sci Rep. 2021 Dec 1;11(1):23216
pubmed: 34853374